Changes this week
Changes detected in the 7 days to Nov 21, 2026
- Minor: ALKS 2680 · Narcolepsy Type 1 Trial sites expanded: 42 → 66 locations
- Minor: GB-0895 Adjunctive Therapy in Adults and · Severe Uncontrolled Asthma (SOLAIRIA-2) Trial sites expanded: 158 → 166 locations
- Minor: Zelpultide Alfa in Preterm Neonates at High Risk of Developing Bronchopulmonary Dysplasia (BPD) Trial sites expanded: 50 → 56 locations
- Minor: EYE201/MK-8748 · Macular Degeneration (MK-8748-002) Trial sites expanded: 132 → 148 locations
- Minor: New Formulation of Oral Cladribine Compared With Placebo · Generalized Myasthenia Gravis (MyClad) Trial sites expanded: 153 → 159 locations
- Minor: Canvuparatide Compared With Placebo · Hypoparathyroidism Trial sites expanded: 22 → 28 locations
- Minor: Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) Trial sites expanded: 168 → 174 locations
- Minor: Xywav Expanded Dosing vs Placebo · Narcolepsy or IH Trial sites expanded: 15 → 27 locations
- Minor: ALKS 2680 · Narcolepsy Type 1 (Brilliance NT1 - 304) Trial sites expanded: 20 → 53 locations
- Minor: Outcomes of Pemvidutide in MASH Trial sites expanded: 9 → 62 locations
- Minor: Efimosfermin Compared With Placebo · Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH) Trial sites expanded: 35 → 39 locations
- Minor: BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer Trial sites expanded: 52 → 77 locations
- Minor: Fenfluramine Hydrochloride in Rett Syndrome Trial sites expanded: 40 → 46 locations
- Minor: Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections · Multiple Myeloma Trial sites expanded: 65 → 68 locations
- Minor: Efimosfermin Alfa Compared With Placebo · Alcohol-related Liver Disease (ALD) Trial sites expanded: 13 → 17 locations
- Minor: Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy · HER2-positive Breast Cancer Trial sites expanded: 53 → 60 locations
- Minor: PIPE 791 · Idiopathic Pulmonary Fibrosis Trial sites expanded: 108 → 111 locations
- Minor: EP-104GI · Eosinophilic Esophagitis (EoE) Trial sites expanded: 23 → 33 locations
- Minor: Afimkibart · Rheumatoid Arthritis Trial sites expanded: 10 → 17 locations
- Minor: LX2006 Gene Therapy in Friedreich Ataxia Cardiomyopathy Trial sites expanded: 1 → 22 locations
- Minor: EPI-326 in EGFR-mutant NSCLC and HNSCC Trial sites expanded: 6 → 12 locations
- Minor: Methylene Blue Photodynamic Therapy · Deep Tissue Abscesses Enrollment increased: 120 → 150 participants
- Minor: S241656 in Selected RAS/MAPK Mutation- Positive Malignancies Enrollment increased: 554 → 623 participants
- Minor: VIR-5500 (AMX-500) in Prostate Cancer Trial sites expanded: 26 → 30 locations
- Minor: CD388/MK1406 on the Immunogenicity of Fluzone® HD Vaccine (CD388.SQ.1.08/MK-1406-007) Trial sites expanded: 4 → 15 locations
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates